G1 Therapeutics Inc (GTHX)

15.07
+0.11(+0.74%)
After Hours
15.05
-0.02(-0.13%)
- Real-time Data
  • Volume:
    619,685
  • Bid/Ask:
    14.85/15.05
  • Day's Range:
    14.86 - 15.30

GTHX Overview

Prev. Close
14.96
Day's Range
14.86-15.3
Revenue
63.97M
Open
15.1
52 wk Range
10.81-36.9
EPS
-2.56
Volume
619,685
Market Cap
633.53M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,008,658
P/E Ratio
-
Beta
2.14
1-Year Change
10.97%
Shares Outstanding
42,348,337
Next Earnings Date
Nov 10, 2021
What is your sentiment on G1 Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

G1 Therapeutics Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellBuyBuyNeutralStrong Sell
Technical IndicatorsStrong SellSellStrong BuyBuyStrong Sell
SummaryStrong SellNeutralStrong BuyNeutralStrong Sell

G1 Therapeutics Inc Company Profile

G1 Therapeutics Inc Company Profile

Employees
122

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer, as well as Phase II clinical trials for the treatment of neoadjuvant breast cancer; lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a collaboration with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment of locally advanced breast cancer; and license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.

Read More
  • Bought for 15.0In case of fail, money will help sbdy )
    0
    • 12 next
      5
      • G1 Therapeutics Cosela is FDA approved drug. One course cost 34 000$ and current target audince is more than 30 000 patients per year. Given near 80% margin it results in potential operationg profit per year of more than 800 mln (34k x 30k x 0,8). But with further FDA approvals for another cancer types target audience will be more than 400k patients. So, you can recalculate potential profitability.Main reason why i'm writing this is that current capitalisation is near 900mln. Analysts target prices are 2,5-4x from current price, but I think that it is much more undervalued and at least 6-7x rise will just give reasonable price to this company. What do you think of this?
        0
        • expecting 4-5m in revenue Q3 depending on delta variant with respect to sales face time. exceedingly more after permenant j-code takes effect in oct.
          0
      • Fasten your seatbelts!
        0
        • 19.5 next week
          0
          • No timka, no!
            0
          • ne armageddon' tut
            0
        • 3x this year 🚀
          0
          • why?
            0
          • Look at the addressable market size for Cosela
            0
        • COSELA Added to Both the NCCN Treatment Guidelines for Small Cell Lung Cancer and the NCCN Supportive Care Guidelines for Hematopoietic Growth Factors 👍👍👍
          0
          • Cosela is now commercialized!!
            0
            • Market is irrational...
              0
          • G1 Therapeutics and Boehringer Ingelheim announce commercial availability of COSELA, the Only FDA-approved
            0
            • earning date today?
              0
              • Announced durung the after hours
                0
            • it is raising
              0
              • Patience will pay off https://shortsqueeze.com/?symbol=Gthx&submit=Short+Quote™
                1
                • I will hold till 70 Medium 35
                  1
                  • anyone know why it came down so much from premarket highs of +40%? Now it's only up 5% in regular hours
                    0
                    • Jonny RetWhy is it garbage? Didn't they just get FDA approval for their drug?
                      1
                    • There is too many shorts now that why its going now dont worry just hold until next week everyone sold today will regret it Will go up again 60+ This cure will make big profits for the company
                      1
                    • Forecast $78 https://www.tipranks.com/stocks/gthx/forecast
                      1
                  • Blast off! 🚀
                    0
                    • just received FDA approval!
                      0
                      • FDA Approved G1 Therapeutics gets FDA approval of Cosela for patients with small cell lung cancer to protect bone marrow function.
                        0
                        • SEC Form SC 13G just filed
                          0
                          • what's it ?
                            0
                        • 🚀
                          0
                          • Fda catalyst expected Feb 15,2021. Lets go $78!!!
                            0
                            • G1 just release PR of the breast cancer treatment drug trilaciclib 2nd final trial very positive and promising. Buckle up! Booster ready.. this one will sky rocket ↗️↗️↗️
                              2
                              • is $19 a good entry point for this?
                                0
                                • Hope you got in at 19
                                  0
                                • Gene Emory yeah bought 300 shares averaged $18
                                  0
                              • Medium target $51, high estimate $82. I love the odd. 👍👍👍
                                0
                                • Whats Moving This?? Thoughts?
                                  0
                                  • tomorrow 25
                                    0
                                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.